Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials
Open Access
- 11 May 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5), e0153740
- https://doi.org/10.1371/journal.pone.0153740
Abstract
Methotrexate (MTX) has been used to treat psoriasis for over half a century. Even so, clinical data characterising its efficacy and safety are sparse. In order to enhance the available evidence, we conducted two meta-analyses, one for efficacy and one for safety outcomes, respectively, according to PRISMA checklist. (Data sources, study criteria, and study synthesis methods are detailed in Methods). In terms of efficacy, only eleven studies met criteria for study design and passed a Cochrane risk of bias analysis. Based on this limited dataset, 45.2% [95% confidence interval 34.1–60.0] of patients achieve PASI75 at primary endpoint (12 or 16 weeks, respectively, n = 705 patients across all studies), compared to a calculated PASI75 of 4.4 [3.5–5.6] for placebo, yielding a relative risk of 10.2 [95% C.I. 7.1–14.7]. For safety outcomes, we extended the meta-analysis to include studies employing the same dose range of MTX for other chronic inflammatory conditions, e.g. rheumatoid arthritis, in order not to maximise capture of relevant safety data. Based on 2763 patient safety years, adverse events (AEs) were found treatment limiting in 6.9 ± 1.4% (mean ± s.e.) of patients treated for six months, with an adverse effect profile largely in line with that encountered in clinical practice. Finally, in order to facilitate prospective clinical audit and to help generate long-term treatment outcomes under real world conditions, we also developed an easy to use documentation form to be completed by patients without requirement for additional staff time. Meta-analyses for efficacy and safety, respectively, employed non-identical selection criteria. These meta-analyses summarise currently available evidence on MTX in psoriasis and should be of use to gauge whether local results broadly fall within outcomes.Keywords
This publication has 52 references indexed in Scilit:
- Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA studyAnnals Of The Rheumatic Diseases, 2012
- A randomized placebo-controlled trial of methotrexate in psoriatic arthritisRheumatology, 2012
- Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH studyAnnals Of The Rheumatic Diseases, 2011
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND studyAnnals Of The Rheumatic Diseases, 2011
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnnals Of The Rheumatic Diseases, 2009
- Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factorsAnnals Of The Rheumatic Diseases, 2009
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialAnnals Of The Rheumatic Diseases, 2008
- Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2007
- Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studyAnnals Of The Rheumatic Diseases, 2006